$0.00
$7.00
bear $0.00
base $0.50
bull $7.00
margin of safety $0.25
market price* $18.09
Business condition attached to the margin of safety
Two consecutive years in which annual gross profit grows faster than operating costs and cash used in operations is shrinking.
Shoulder Innovations makes shoulder replacement implants. Its products are the InSet Glenoid and InSet humeral stem systems, used in anatomic and reverse total shoulder replacements, plus a preoperative planning tool called ProVoyance. Since the first InSet launch in 2016 the implants have been used in more than 17,500 procedures. The company went public in 2025 and sells to hospitals and ambulatory surgery centers, partly through independent distributors. What the business earns today. Revenue grew from $31.6 million in 2024 to $47.3 million in 2025 (about 50%), and to $33.9 million in the first half of 2026 versus $21.1 million a year earlier (about 60%). Gross margin is high, about 76.5% in 2025. But spending has grown faster than gross profit. Net cash used in operations was $14.1 million in 2024 and $28.6 million in 2025, and $19.8 million in the first half of 2026 versus $11.3 million a year earlier. Our owner-earnings measure (operating cash flow, less working-capital swings such as inventory build, less stock compensation, less the maintenance portion of capital spending) was about negative $17.9 million in 2024 and negative $28.0 million in 2025, or roughly negative $0.87 and negative $1.36 per share on the 20.6 million shares outstanding at the end of 2025. Only two years of statements exist because the company recently listed, so the anchor is the median of those two years, which is negative. The 2025 figure includes an $11.975 million non-cash charge from changes in the value of warrants and a purchase option, which is added back because it involves no cash. Rebuilding the figure from net loss plus non-cash charges, less maintenance capital spending, gave the same result. What the shares are worth. The company held $124.3 million of cash and marketable securities at the end of 2025 against $15.0 million of principal on a Trinity Capital term loan that is due September 1, 2028. That is about $109 million of net cash, or roughly $5.29 per share, but the company is spending it. Nothing in the filings shows the business earning a profit today, and rapid growth, new products and future margin gains are not locked in, so we give them no credit in the base case or the bear case. Bear case, $0 per share. Losses keep widening at about the first-half 2026 pace, roughly $49 million a year of operating cash burn plus equipment purchases, and the cash is used up in a little over two years with no earnings to replace it. The loan comes due in September 2028. Existing shareholders are left with nothing, and any new financing would likely dilute them. Base case, $0.50 per share. The business is worth what remains of its net cash after funding losses at the recent pace for two years: $109 million less about $99 million leaves roughly $11 million, or about $0.50 per share. We do not credit any future profits because no profitable year exists yet and the growth is only two years old, with no downturn tested. Bull case, about $7 per share. Here the company's own levers work. Revenue growth, 60% in the first half of 2026, fades from 45% to 8% over ten years, gross margin holds near 77% as it has in 2024 and 2025, and spending growth slows from 30% to 5% a year. Operating cash flow turns positive in about the seventh year, then earnings are held flat for ten more years and valued at zero after that. This adds to the net cash and gives roughly $7 per share. It requires the company to control spending, which it has not yet done. Growth-path check. Owner earnings worsened in 2025 (from negative $17.9 million to negative $28.0 million), and the first half of 2026 is worse again, so we assume no improvement in the near term in any case. What could make this wrong. Gross profit rose $11.9 million in 2025 and $10.2 million in the first half of 2026 versus the same period a year earlier, so if management holds spending flat while sales keep climbing, the business could reach break-even much sooner than the base case allows. The new InSet 70 stem, launched in September 2025, and an FDA 510(k) clearance received in January 2026 could add products, but we do not credit them. Conversely, a further step-up in spending or inventory would deplete the cash faster. The company states that existing cash, securities and the loan should fund planned operations for at least 12 months from the filing date.